Small Business Technology Transfer (STTR) Program

Small Business Technology Transfer (STTR) Program is sponsored by U.S. National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA). The STTR program supports small businesses to develop and commercialize innovative technologies, specifically encouraging formal collaboration between small businesses and U. S.

non-profit research institutions.

NOT-OD-04-016: SMALL BUSINESS INNOVATION RESEARCH (SBIR) AND SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) GRANT PROGRAMS SMALL BUSINESS INNOVATION RESEARCH (SBIR) AND SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) GRANT PROGRAMS RELEASE DATE: January 6, 2004 National Institutes of Health (NIH) Centers for Disease Control and Prevention (CDC) Food and Drug Administration (FDA) SBIR/STTR Grant Application Submission Dates: AIDS and AIDS-related SBIR/STTR Grant Application Submission Dates: The purpose of this notice is to (1) announce the issuance of the SOLICITATION of THE NATIONAL INSTITUTES OF HEALTH (NIH), CENTERS for DISEASE CONTROL AND PREVENTION (CDC), and FOOD AND DRUG ADMINISTRATION FDA) for SMALL BUSINESS INNOVATION RESEARCH (SBIR) and SMALL BUSINESS TECHNOLOGY TRANSFER STTR) GRANT APPLICATIONS (PHS 2004-2) and (2) inform the public about the opportunities that the SBIR/STTR programs offer to small business concerns.

The NIH, CDC, and FDA invite eligible small business concerns to submit Phase I grant applications for the Calendar Year (CY) 2004 SBIR program and, applicable to NIH only, for United States small business concerns that have the research capabilities and technological expertise to contribute to the research or research and development (R/R&D) mission(s) of the NIH, CDC and the FDA awarding components identified in this solicitation are encouraged to submit SBIR/STTR grant applications in response to identified topics.

Applicants may also consider other areas of research within the mission of an Institute/Center (IC) and submit an investigator- initiated SBIR/STTR application. The submission dates for grant applications in response to the PHS 2004-2 are noted above. Effective with the release of the PHS 2004-2 Solicitation, CDC will accept SBIR applications for the SAME THREE dates as NIH and FDA: April 1, August 1, and December 1.

Eligibility requirements, definitions, application procedures, review considerations, application forms and instructions, and other pertinent information are contained in the PHS 2004-2 OMNIBUS SOLICITATION of the NATIONAL INSTITUTES of HEALTH, CENTERS for DISEASE CONTROL and PREVENTION, and FOOD AND DRUG ADMINISTRATION for SMALL BUSINESS INNOVATION RESEARCH (SBIR) and SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) GRANT APPLICATIONS.

The solicitation, including application forms, is available page. See http://grants. nih.

gov/grants/funding/sbir. htm . The SBIR and STTR legislation requires the Public Health Service (PHS), Department of Health and Human Services, and certain other federal agencies to reserve 2.

5 percent of their extramural R/R&D budgets for an SBIR program and 0. 3% of their extramural R/R&D budgets for an STTR program. The PHS SBIR and STTR set-aside requirements for FY 2004 are estimated to be $600 million.

The goals of the SBIR and STTR programs are to stimulate technological innovation in the private sector, strengthen the role of small business concerns in meeting Federal research and development needs, increase the commercial application of federally supported research results, and foster and encourage participation by socially and economically disadvantaged persons and women-owned small businesses in technological innovation.

The STTR program further expands the goals through cooperative R/R&D carried out between small business concerns and research institutions. Innovative technologies and methodologies fuel progress in biomedical and behavioral research and represent an increasingly important area of the economy.

The SBIR and STTR programs provide support for R/R&D of new technologies and methodologies that have the potential to succeed as commercial products, processes or The SBIR and STTR programs consist of three phases: PHASE I: The objective of Phase I is to establish the technical merit and feasibility of the proposed R/R&D efforts and to determine the quality of performance of the small business grantee organization prior to providing further Federal support in Phase II.

Preliminary data is not required. SBIR/STTR Phase I awards normally may not exceed $100,000 total costs (direct costs, Facilities & Administrative [F&A] costs, and fee) for a period normally not to exceed 6 months (SBIR) or one year (STTR). For SBIR projects, the total amount of all contractual costs and consultant fees normally may not exceed 33% of the total costs requested.

For STTR projects, the small business must perform a minimum of 40% of the R/R&D and the single partnering U.S. research institution must perform a minimum of 30% of the R/R&D. PHASE II: The objective of Phase II is to continue the R/R&D efforts initiated in Phase I.

Funding shall be based on several factors including the feasibility results of Phase I, scientific and technical merit, and commercial potential of the Phase II application. SBIR/STTR Phase II awards normally may not exceed $750,000 in total costs (direct costs, F&A costs, and fee) for a period normally not to exceed 2 years.

Only Phase I grantees are eligible to obtain Phase II funding, and only one Phase II award may be made for a single SBIR/STTR project. Not all types of biomedical and behavioral research can be completed within the statutory award amounts for Phase I ($100,000) or Phase II ($750,000) and statutory project periods (six months for Phase I; two years for Phase II).

Applicants are encouraged to propose a budget and project period that is reasonable and appropriate for completion of the research project. Deviations from the statutory guidelines MUST be well justified and must be discussed with appropriate NIH staff listed below.

Note: CDC and FDA do NOT make awards greater than the stated PHASE III: The objective of Phase III is for the small business concern to pursue with non-SBIR/STTR funds (either Federal or non-Federal) the commercialization objectives resulting from the results of the research or R&D funded in Phases I and II.

In some Federal agencies, Phase III may involve follow-on, non-SBIR/STTR funded R&D, or production contracts for products or processes intended for use by the U.S. Applicants are strongly encouraged to contact NIH program staff named below prior to submitting an SBIR/STTR grant application for information regarding research topics. National Institute on Aging Dr. Michael-David A. R.

R. Kerns National Institute on Alcohol Abuse and Alcoholism National Institute of Allergy and Infectious Diseases National Institute of Arthritis and Musculoskeletal and Skin Diseases http://www. niams.

nih. gov/ National Institute of Biomedical Imaging and Bioengineering http://www. nibib.

nih. gov/ National Cancer Institute National Institute of Child Health and Human Development National Institute on Drug Abuse National Institute on Deafness and Other Communication Disorders National Institute of Dental and Craniofacial Research National Institute of Diabetes and Digestive and Kidney Diseases National Institute of Environmental Health Sciences National Institute of General Medical Sciences http://www. nigms.

nih.

gov/ National Heart, Lung, and Blood Institute National Human Genome Research Institute National Institute of Mental Health National Institute of Neurological Disorders and Stroke National Institute of Nursing Research National Center for Research Resources National Center for Complementary and Alternative Medicine National Center on Minority Health and Health Disparities Mr. Vincent Thomas, MSW, MPA National Library of Medicine Centers for Disease Control and Prevention (CDC) Food and Drug Administration (FDA) Weekly TOC for this Announcement NIH...

Turning Discovery Into Health ®